January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]
December 1st, 2020 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of diagnostic and therapeutic products in oncology and research services provider, announces today the opening of its new office in Boston at the Cambridge Innovation Center (CIC). United States is one of the priority markets for the organization and [...]
November 25th, 2020 PROALT’s project proposal named ‘METASTCURE – Anti cadherin-RGD monoclonal antibody PA-0661 for the treatment of metastatic colorectal cancer’ has received the Seal of Excellence recognition from the Enhanced European Innovation Council (EIC) pilot in EU. The EIC Accelerator programme is part of the Enhanced European Innovation Council pilot and provides grant and blended [...]
October 26th, 2020 BIO-Europe is the largest partnering conference in Europe dedicated to the global biotechnology industry. On this occasion, it will be held in digital format from October 26 to 29. The conference brings together delegates from the entire value chain of the biotech industry, who come to event to identify, negotiate and start [...]
September 28th, 2020 AseBio Investor Day 2020 is a digital event from September 28th to October 1st, organized by the Spanish Association of Bioempresas (AseBio), together with the Biotechnology Market Platform (Ministry of Science), Innovation and Universities, the Institute of Foreign Trade (ICEX) and the BioVoices project. PROALT will participate in the partnering event and [...]
April 1st, 2020 The project proposal named ‘PROFILUX – Saliva- and blood-based lung cancer detection based on tumour auto-antibody profiling’ has been selected to receive funding from the EU Eurostars Programme. The company received the official communication in January and the project started on April. The international research consortium where PROALT participates is leaded by [...]
23rd, April 2019 Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based on detecting in blood the autoantibodies (AAbs) generated by the human body against proteins related to the colorectal cancer tumor, known as tumor-associated antigens [...]
1st, October 2018 From September 25 to 27, the meeting organized by ASEBIO and the Junta de Andalucía brought together in Seville the largest national and international agents in the biotechnology sector. PROALT has participated in the partnering event and met during these days with investors, customers and potential commercial and technological partners. The company [...]
Photo: partnering meetings at BIO 2018. 6th, June 2018 PROALT has participated in the partnering event at BIO International Convention in Boston, MA (USA), to present the latest advances of COLODETECT, the non-invasive test in development by the company that will allow early detection of colorectal cancer (CCR) in patients affected by this disease, even [...]
14th, March 2018 BIOEUROPE SPRING 2018 is the premier springtime partnering conference for the biotechnology industry. Amsterdam, The Netherlands. 12th-14th March 2018. The company participated in the conference and partnering event to promote its activities in colorectal cancer diagnostic and therapeutic fields, highlighting the latest progresses. Investors had the chance to update about the of [...]
Copyright ©2020 Protein Alternatives SL. All rights reserved | Legal Notice & Privacy Policy
